Corporation
Janssen Inc.
- Meetings this Parliament
- 13
- With MPs
- 3
- Since Nov 2021
- 44
- Active registrations
- 1
Most recent reported meeting: Aug 21, 2026.
Lobbying by Janssen Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Feb 12, 2026
Filed by Laetitia Decroix Guilloux, President
Lobbyists
- Alaine Grand · Vice President, Market Access & Strategic Customers
- Donald Elrick · Head of Regulatory Affairs and Commercial Quality
- Laetitia Decroix Guilloux · President
- Monica Da Re · Senior Manager, Government Affairs & Policy
Institutions they may lobby: Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Justice Canada (JC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (17)Hide details
- Canadian Drug Agency: the mandate and creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives, including patient access and reimbursement framework.
- Communications regarding Canada’s mental health strategy, implementation and access to services for Canadians.
- Development of Health Emergency Readiness Canada agency, and role in promoting development life sciences sector.
- Subsequent Entry Biologics (SEBs): the need for regulatory amendments to facilitate their approval.
- Research and Development (R&D): Input on Canada's clinical trial approval and implementations processes; Investing in Canada in R&D.
- Proposed national pharmacare: Specifically, government’s intention to introduce a national pharmacare program.
- Modernization of Food & Drug Act: support for proposed regulatory changes, modernization and international harmonizations with other regulatory bodies (European Medicines Agency/U.S. Food and Drug Administration).
- Input into the Patented Medicines Price Review Board evaluation of annual R&D investments by companies in Canada based on Scientific Research and Experimental Development (SR&ED) tax rules. Working with PMPRB and legislators to ensure appropriate measures of R&D investment are in place.
- Incentives and programs to attract and support manufacturing activities in Canada
- Health Canada and the Patented Medicine Prices Review Board(PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.
- Health Canada's enforcement of Canada's Food and Drugs Act and Regulations as they relate to the cross border sale of drugs to the United States.
- COVID-19: Regarding the development of a COVID-19 vaccine & policies and related to the COVID-19 pandemic.
- Comprehensive Economic Trade Agreement with Europe (CETA) and pharmaceutical intellectual property protection.
- Communications regarding the maintenance of domestic supply of essential drug products.
- Canada-United States-Mexico Agreement (CUSMA) and pharmaceutical intellectual property protection.
- Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement.
- An amendment to the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations") regarding the right to appeal.
Registration 962820-14483-49. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Berkeley Vincent (25), Laetitia Decroix Guilloux (8), Jorge Bartolome (7), Alaine Grand (4).
-
Reported by Berkeley Vincent · In-house (corporation)
- Stan Kutcher · Senator, Senate of Canada
HealthIndustry
-
Reported by Berkeley Vincent · In-house (corporation)
- Andrew Cardozo · Senator, Senate of Canada
HealthIndustry
-
Reported by Berkeley Vincent · In-house (corporation)
- Ben Chin · Senior Advisor, Prime Minister's Office (PMO)
HealthIndustry
-
Reported by Berkeley Vincent · In-house (corporation)
- Stephen Lucas · Deputy Minister, Health Canada (HC)
HealthIndustry
-
Reported by Berkeley Vincent · In-house (corporation)
- Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Stephen Lucas · Deputy Minister, Health Canada (HC)
- Chris Johnstone · Assistant Deputy Minister, Health Canada (HC)
Economic DevelopmentHealthIndustry
-
Reported by Berkeley Vincent · In-house (corporation)
- Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Stephen Lucas · Deputy Minister, Health Canada (HC)
HealthIndustry
-
Reported by Berkeley Vincent · In-house (corporation)
- Cyndi Jenkins · Chief of Staff, Health Canada (HC)
HealthIndustry
-
Reported by Berkeley Vincent · In-house (corporation)
- Brian Clow · Deputy Chief of Staff, Prime Minister's Office (PMO)
HealthIndustry
-
Reported by Berkeley Vincent · In-house (corporation)
- Mark Schaan · Senior Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Industry
-
Reported by Berkeley Vincent · In-house (corporation)
- Cory Pike · Chief of Staff, Public Services and Procurement Canada (PSPC)
HealthPrivacy and Access to Information
-
Reported by Berkeley Vincent · In-house (corporation)
- Cory Pike · Chief of Staff, Public Services and Procurement Canada (PSPC)
HealthPrivacy and Access to Information
-
Reported by Berkeley Vincent · In-house (corporation)
- Eric Costen · Senior Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Eric Belair · Associate Assistant Deputy Minister, Health Canada (HC)
HealthIndustry
-
Reported by Jorge Bartolome · In-house (corporation)
- Peter M. Boehm · Senator, Senate of Canada
IndustryInternational Trade
-
Reported by Jorge Bartolome · In-house (corporation)
- Boyan Gerasimov · Director of Policy, Innovation, Science and Economic Development Canada (ISED)
- Bianca Hossain · Senior Special Assistant (Policy and Operations), Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by Jorge Bartolome · In-house (corporation)
- Daniel Blaikie · Member of Parliament, House of Commons
BudgetIndustry
-
Reported by Jorge Bartolome · In-house (corporation)
- Sacha Atherly · Director of Policy, Global Affairs Canada (GAC)
- Jean-Sebastien Bock · Director of Policy, Health Canada (HC)
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
Health
-
Reported by Jorge Bartolome · In-house (corporation)
- François-Philippe Champagne · Minister of International Trade, Global Affairs Canada (GAC)
Industry
-
Reported by Jorge Bartolome · In-house (corporation)
- Jeremy Bruce · Policy Advisor, Global Affairs Canada (GAC)
Industry
-
Reported by Jorge Bartolome · In-house (corporation)
- François-Philippe Champagne · Minister of Innovation, Science and Industry, Innovation, Science and Economic Development Canada (ISED)
HealthIntellectual Property
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.